Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Ipca Laboratories Ltd.'s net profit margin of 8.7% in FY2025 reflects thin profitability, with operating margin at 15.7% and gross margin at 69.2%.
In FY 2025, Ipca Laboratories Ltd. posted a gross margin of 69.2%, an operating margin of 15.7%, a net margin of 8.7%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Ipca Laboratories Ltd.'s revenue grew 15.4% to 90.32B and net profit grew 50.2% to 7.85B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Ipca Laboratories Ltd.'s revenue grew by 15.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Ipca Laboratories Ltd.'s ROE of 9.4% in FY2025 indicates below-average shareholder returns.
In FY 2025, Ipca Laboratories Ltd. reported an ROE of 9.4%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Ipca Laboratories Ltd.'s FCF/NI ratio of 0.70x in FY2025 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2025, Ipca Laboratories Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Ipca Laboratories Ltd.'s OCF/NI ratio of 1.68x in FY2025 indicates strong cash collection and working capital efficiency.
In FY 2025, Ipca Laboratories Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Ipca Laboratories Ltd.'s current ratio of 2.63x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Ipca Laboratories Ltd. reported a current ratio of 2.63. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Ipca Laboratories Ltd.'s interest coverage ratio of 16.7x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Ipca Laboratories Ltd. reported an interest coverage ratio of 16.7x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Ipca Laboratories Ltd.'s debt-to-equity ratio of 0.16x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Ipca Laboratories Ltd. reported a debt-to-equity ratio of 0.16. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Ipca Laboratories Ltd.'s debt decreased 5.3% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Ipca Laboratories Ltd.'s total debt decreased by 5.3% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Ipca Laboratories Ltd.'s diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 253.67M.
In FY 2025, Ipca Laboratories Ltd.'s diluted shares decreased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025